UC College of Medicine researcher receives $1.7 million grant to study cardiac hypertrophy

May 13, 2016

CINCINNATI--A new $1.7 million National Institutes of Health grant will help University of Cincinnati (UC) researchers continue their investigation of the protein Human Antigen R (HuR) and its possible role in cardiovascular disease, with the ultimate goal of translating this research to improve human health.

Using animal models of heart disease, researchers are able to surgically restrict the amount of blood flowing through the aorta resulting in an increase in the pressure the heart must pump against, causing cardiac muscle to enlarge, called hypertrophy. Cardiac hypertrophy often progresses to heart failure, and there are currently no treatments for the underlying cause of hypertrophy at the level of the myocyte, or cardiac muscle cell.

"What we have found is when we delete this protein in the myocytes, normal cardiac function is unaffected, but the mice lacking HuR are protected from hypertrophy and heart failure," explains Michael Tranter, assistant professor in the UC College of Medicine's Division of Cardiovascular Health and Disease. "All of our evidence so far suggests that activation of HuR in the adult heart is only affecting the pathology, making it an ideal target."

Tranter, a researcher at the UC Heart, Lung and Vascular Institute, received a five-year grant (R01HL132111) from the NIH's National Heart, Lung and Blood Institute, to determine why and how the HuR protein is activated and how to duplicate the process. The grant's principal investigator Tranter is also collaborating with co-investigator, Jack Rubinstein, MD, assistant professor in the UC College of Medicine and UC Health cardiologist.

Rubinstein says Tranter's research will be very helpful in understanding how the heart reacts when subjected to high blood pressure.

"This line of research is particularly important as hundreds of thousands of people, especially older patients, develop heart problems, including heart failure as a result of suffering from high blood pressure," says Rubinstein. The American Heart Association estimates that roughly one in four Americans currently suffers from high blood pressure.

Tranter and Rubinstein, along with colleagues Phillip Owens, PhD, and Kevin Haworth, PhD, both also assistant professors in UC College of Medicine's Division of Cardiovascular Health and Disease, are part of a recent investment in young investigators by the College of Medicine. While their average age is only 36, they have together already been awarded over $4 million in external research funding from sources such as the NIH and the American Heart Association. At age 34, Tranter is nearly a decade younger than the average first-time R01 recipient.

"Dr. Tranter has distinguished himself in a highly competitive area of cardiovascular research," says Richard Becker, MD, director and physician-in-chief of the UC Heart, Lung and Vascular Institute. "His personal achievements and those of his collaborative group are laudable and represent in most tangible terms the Institute's mission to serve through impactful science".
-end-


University of Cincinnati Academic Health Center

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.